F. HOFFMANN-LA ROCHE AG;NANOSTRING TECHNOLOGIES, INC.
发明人:
OESTERGAARD, MIKKEL ZAHLE
申请号：
CA3071618
公开号：
CA3071618A1
申请日:
2018.08.08
申请国别(地区):
CA
年份:
2019
代理人:
摘要：
The present invention relates to obinutuzumab (or its functional equivalents)for use in the treatment of a particularbiomarker-defined DLBCL patient and a novel DLBCL patient subgroup,respectively. The present invention further relates to a methodfor treating DLBCL with obinutuzumab (or its functional equivalents) in apatient in need thereof, wherein said patient is a particularbiomarker-defined DLBCL patient or belongs to a novel biomarker-defined DLBCLpatient subgroup. The present invention furtherrelates to the use of obinutuzumab (or its functional equivalents) for thepreparation of a pharmaceutical composition for the treatmentof DLBCL in the particular biomarker-defined DLBCL patient/novel DLBCL patientsubgroup. The present invention further relatesto a method for identifying a particular DLBCL patient/novel DLBCL patientsubgroup and a method for diagnosing a novel form ofDLBCL and a particular DLBCL patient/novel DLBCL patient subgroup,respectively.
